Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate
about
Epicardial calcineurin-NFAT signals through Smad2 to direct coronary smooth muscle cell and arterial wall development.Cytosolic H2O2 mediates hypertrophy, apoptosis, and decreased SERCA activity in mice with chronic hemodynamic overload.Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxiaNeurobiology of vascular dementia.Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trialBlood gas analysis and cooximetry in retired racing Greyhounds.PET imaging of cardiac hypoxia: opportunities and challenges.Hemoglobin conjugates with antioxidant enzymes (hemoglobin-superoxide dismutase-catalase) via poly(ethylene glycol) crosslinker for protection of pancreatic beta RINm5F cells in hypoxiaShould modulation of p50 be a therapeutic target in the critically ill?Increasing the oxygen load by treatment with myo-inositol trispyrophosphate reduces growth of colon cancer and modulates the intestine homeobox gene Cdx2.Cardiac-specific overexpression of catalase identifies hydrogen peroxide-dependent and -independent phases of myocardial remodeling and prevents the progression to overt heart failure in G(alpha)q-overexpressing transgenic mice.Examining the relationship between exercise tolerance and isoproterenol-based cardiac reserve in murine models of heart failure.Screening and confirmation of myo-inositol trispyrophosphate (ITPP) in human urine by hydrophilic interaction liquid chromatography high resolution / high accuracy mass spectrometry for doping control purposes.Detection of myo-inositol tris pyrophosphate (ITPP) in equine following an administration of ITPP.Allosteric Effectors of Hemoglobin: Past, Present and FutureExploring the origins of structure–oxygen affinity relationship of human haemoglobin allosteric effector
P2860
Q33163160-DF8F06B3-335C-4DA4-9C4B-F703A420AC3DQ33626525-EAAC4D53-8944-4D49-B950-75A3ADB34488Q33798508-FCB8E97D-D3B7-48FF-8DA3-E49446071E22Q35176496-E4AD850E-0A15-4057-80BD-5DADB293C05DQ36166723-30E78883-196C-4CF3-9675-8A48FDEC26BDQ37276012-26C7A771-6F42-4FBE-8C15-E66764EBBF2DQ37904019-1534C414-309F-42B4-9696-CE01318702C2Q38556542-55417962-8E66-4EB0-B34C-DBD5AEA75636Q39237387-DD550CA2-0558-40A1-951F-8A2482896FA6Q39263962-60A405E8-11E2-4E86-8F79-72C26A83C36CQ42702321-952E87EB-3199-4448-90B1-5D2D4C8E1311Q48031125-B5022AFE-C93F-4ABA-AB15-7BD941B4A529Q50464190-7A8D6AC9-12C8-4128-B3CA-D7AC5F6E51E6Q50490183-B1BD2814-2EB2-49EB-A402-AE0A1CBA1A94Q53411271-0D4B69CA-085F-48F8-980B-5E2D53CD8284Q57011482-3E65CBF3-E1C5-4E42-9AB4-05D06B2A3710
P2860
Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Enhanced exercise capacity in ...... myo-inositol trispyrophosphate
@en
Enhanced exercise capacity in ...... yo-inositol trispyrophosphate.
@nl
type
label
Enhanced exercise capacity in ...... myo-inositol trispyrophosphate
@en
Enhanced exercise capacity in ...... yo-inositol trispyrophosphate.
@nl
prefLabel
Enhanced exercise capacity in ...... myo-inositol trispyrophosphate
@en
Enhanced exercise capacity in ...... yo-inositol trispyrophosphate.
@nl
P2093
P2860
P50
P356
P1476
Enhanced exercise capacity in ...... myo-inositol trispyrophosphate
@en
P2093
Andreia Biolo
Carolina D Duarte
Claude Nicolau
Deborah A Siwik
Eugene Valsky
Konstantina C Fylaktakidou
Richard P Schwarz
Ruth Greferath
Srinivasu Pothukanuri
P2860
P304
P356
10.1073/PNAS.0812381106
P407
P577
2009-02-09T00:00:00Z